MRA: FDA accepts four new States
After a positive assessment, the US Food and Drug Administration (FDA) has approved four additional EU Member States to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
In November 2018, the FDA confirmed the capability of Belgium, Denmark, Finland and Latvia. This means that the FDA can now rely on a total of 19 Member States to replace their own inspections - in addition to those mentioned these are:Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Related GMP News
03.09.2025FDA Report on the State of Pharmaceutical Quality
27.08.2025Bizarre Findings in FDA Warning Letters
27.08.2025FDA Warning Letter with a diverse List of Deficiencies
06.08.2025Root Cause Analysis: Problems continue
16.07.2025Final FDA Guidance on Remote Regulatory Assessments
02.07.2025EFPIA Report on Current Inspections